News
ONTXW
0.0671
0.00%
0.00
ONCONOVA THERAPEUTICS INC - TRAWS WILL BE LED BY INCOMING CHIEF EXECUTIVE OFFICER, WERNER CAUTREELS
Reuters · 04/02 11:00
Onconova Therapeutics Inc <ONTX.OQ> expected to post a loss of 25 cents a share - Earnings Preview
Onconova Therapeutics Inc expected to post a loss of 25 cents a share. The company is expected to report a 16.7% increase in quarterly revenue to $65.33 thousand. The mean analyst estimate for Onconova's quarterly revenue is for a 25 cents a share loss.
Reuters · 03/15 20:27
Onconova Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Reuters · 08/10/2023 21:02
BRIEF-Onconova Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
Reuters · 05/15/2023 21:45
BRIEF-Onconova Therapeutics Doses First Patient In Phase 1/2a Trial Of Narazaciclib Combined With Letrozole In Endometrial Cancer
Reuters · 05/11/2023 12:59
More
Webull provides a variety of real-time ONTXW stock news. You can receive the latest news about ONCONOVA THERAPE through multiple platforms. This information may help you make smarter investment decisions.
About ONTXW
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).